Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL407292

CC1(C)CC(C(CCCCCCCC(=O)O)(C(=O)O)C2CC(C)(C)NC(C)(C)C2)CC(C)(C)N1.N

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.37
TSHR P16473 5/20 0.35
LMNA P02545 2/20 0.35
NFKB1 P19838 1/20 0.35
PMP22 Q01453 1/20 0.35
GPR84 Q9NQS5 7/20 0.34
PPARG P37231 7/20 0.34
PPARD Q03181 7/20 0.34
PPARA Q07869 7/20 0.34
HDAC11 Q96DB2 5/20 0.34
PTPN1 P18031 3/20 0.34
ALDH1A1 P00352 2/20 0.34
TLR2 O60603 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
FABP4 P15090 2/20 0.34
SLC22A6 Q4U2R8 1/20 0.34
SLC22A8 Q8TCC7 1/20 0.34
MEN1 O00255 1/20 0.34
ESR1 P03372 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL17080412 1.00 GAA (0.37) GAATSHRLMNANFKB1PMP22
SCHEMBL434149 0.98 GAA (0.38) GAATSHRLMNANFKB1PMP22
SCHEMBL9577728 0.98 GAA (0.38) GAATSHRLMNANFKB1PMP22
SCHEMBL431527 0.98 GAA (0.38) GAATSHRLMNANFKB1PMP22
Sebacic Acid SCHEMBL28872453 0.98 GAA (0.38) GAATSHRLMNANFKB1PMP22
SCHEMBL35143 0.98 GAA (0.38) GAATSHRLMNANFKB1PMP22
SCHEMBL9577600 0.97 GAA (0.38) GAATSHRLMNANFKB1PMP22
SCHEMBL315238 0.94 GAA (0.38) GAALMNASLC22A6KMT2AHTT
SCHEMBL8226136 0.93 GAA (0.35) GAATSHRLMNANFKB1PMP22
SCHEMBL5955261 0.93 GAA (0.35) GAATSHRLMNANFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101094-B2 Terpene, terpenoid, and fullerene stabilizers for fluoroolefins E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-01-24 US claimed
US-9018420-B2 Use of supported ionic liquid phase (SILP) catalyst systems in the hydroformylation of olefin-containing mixtures to aldehyde mixtures with a high content of aldehydes unbranched in the 2 position EVONIK OXENO GMBH (DE) 2015-04-28 US disclosed
US-20130289313-A1 USE OF SUPPORTED IONIC LIQUID PHASE (SILP) CATALYST SYSTEMS IN THE HYDROFORMYLATION OF OLEFIN-CONTAINING MIXTURES TO ALDEHYDE MIXTURES WITH A HIGH CONTENT OF ALDEHYDES UNBRANCHED IN THE 2 POSITION EVONIK OXENO GMBH (DE) 2013-10-31 US disclosed
US-5705083-A Stabilizing leather against thermal and photochemical decomposition CIBA SPECIALTY CHEMICALS CORPORATION (US) 1998-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289313-A1 USE OF SUPPORTED IONIC LIQUID PHASE (SILP) CATALYST SYSTEMS IN THE HYDROFORMYLATION OF OLEFIN-CONTAINING MIXTURES TO ALDEHYDE MIXTURES WITH A HIGH CONTENT OF ALDEHYDES UNBRANCHED IN THE 2 POSITION OR10J3, H1-0, HRH4 GAA 4195/4885TSHR 4595/4885LMNA 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.